脑脊液 Tau 蛋白可辅助 14-3-3 蛋白检测用于散发性克雅氏病的诊断，同时也在向新一代诊断方法过渡。
CSF Tau supplements 14-3-3 protein detection for sporadic Creutzfeldt-Jakob disease diagnosis while transitioning to next generation diagnostics.
作者信息
Li Qiao-Xin, Varghese Shiji, Sarros Shannon, Stehmann Christiane, Doecke James D, Fowler Christopher J, Masters Colin L, Collins Steven J
机构信息
National Dementia Diagnostics Laboratory, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville 3010, Australia.
National Dementia Diagnostics Laboratory, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville 3010, Australia; ANCJDR, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville 3010, Australia.
出版信息
J Clin Neurosci. 2018 Apr;50:292-293. doi: 10.1016/j.jocn.2018.01.064.
The pre-mortem clinical diagnosis of Creutzfeldt-Jakob disease (CJD) is supported by biomarkers, especially cerebrospinal fluid (CSF) 14-3-3 and total tau (Tau) protein levels. These CSF biomarkers have proven the most useful prior to transitioning to powerful next generation diagnostics employing protein amplification techniques such as the real time quaking-induced conversion (RT-QuIC) assay. To enhance national diagnostic capacity while transitioning to RT-QuIC assays an optimized CSF Tau cutoff was determined and shown to usefully supplement 14-3-3 protein detection.
克雅氏病（CJD）的死前临床诊断得到生物标志物的支持，尤其是脑脊液（CSF）中14-3-3和总tau蛋白水平。在转向采用蛋白质扩增技术（如实时震颤诱导转化（RT-QuIC）检测）的强大下一代诊断方法之前，这些脑脊液生物标志物已被证明是最有用的。为了在转向RT-QuIC检测时提高国家诊断能力，确定了优化的脑脊液tau蛋白临界值，并证明其可有效补充14-3-3蛋白检测。
Zotero 插件